A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B

Trial Profile

A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Factor VIIa-CTP (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions
  • Sponsors OPKO Health
  • Most Recent Events

    • 07 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 May 2017.
    • 07 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 Mar 2017.
    • 23 Feb 2016 The first patient in this trial has been dosed, according to an OPKO Health media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top